TAT 4
Alternative Names: TAT4 gelLatest Information Update: 08 Oct 2021
Price :
$50 *
At a glance
- Originator Topokine Therapeutics
- Developer AbbVie
- Class Skin disorder therapies
- Mechanism of Action Adipocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Facial wrinkles; Lipodystrophy
Most Recent Events
- 08 Oct 2021 No development reported - Phase-II for Facial wrinkles in USA (Topical)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for phase-I development in Lipodystrophy in USA (Topical, Gel)